OnLume has imaging technology for Fluorescence Guided Surgery (FGS). FGS illuminates critical anatomy to optimize surgical precision, leading to improved patient outcomes, reduced morbidity and reduced costs.
OnLume’s Chairman and Co-founder Thomas “Rock” Mackie, stated, “With the appointment of Jim Bowman, we continue developing our core team in advance of market launch. Jim’s experience in launching innovative medical technologies expands our commitment and capability for a major impact in the surgical imaging market.”
Bowman has spent his entire career advancing innovative life science technologies. He earned a bachelor of science degree in bioMedical engineering from Marquette University in Milwaukee. He is also a graduate of Harvard Business School’s OPM program, focused on entrepreneurial strategy and operations.
Bowman has held senior leadership positions in growing medtech companies including as CEO, president and director of public and private medical device companies. He has driven the business development of disruptive technologies in firms such as C.R. BARD, Ohmeda (BOC Healthcare), Surgical Laser Technologies, CloudCath, Encision and PharmaJet, where he has been focused on technologies that advance the standard of care and improve patient outcome.
Adam Uselmann, OnLume’s president, chief technology officer and co-founder, said, “Our patented innovations expand the market potential of FGS across a broad range of surgical specialties, with a total available market of $8 billion in the United States.”